Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study

Bidder, Therese; Sahota, Jagdeep; Rennie, Catherine; Lund, Valerie J.; Robinson, Douglas S.; Kariyawasam, Harsha H.

doi:10.4193/rhino17.139

Cited by 21 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 45 A study comparing omalizumab with sinus surgery in grade 3 CRSwNP patients concluded equal effectiveness in reducing the SNOT‐22 scores. 46 With the available evidence, biologics show a modest reduction in polyp size. As revision surgeries cannot prevent recurrence in these patients with type 2 inflammation, it may be likely that biologics will become an alternative therapeutic option to sinus surgery in the future.…”

Section: Discussionmentioning

confidence: 99%

Assessment of chronic rhinosinusitis with nasal polyps: Development of the Nasal Polyp Patient Assessment Scoring Sheet tool

Alsaleh,

Kamal,

Hopkins

et al. 2024

Laryngoscope Investig Oto

View full text Add to dashboard Cite

BackgroundChronic rhinosinusitis (CRS) is a heterogeneous disorder with a wide range of validated subjective and objective assessment tools to assess disease severity. However, a comprehensive and easy‐to‐use tool that integrates these measures for determining disease severity and response to treatment is still obscure. The objective of this study was to develop a standardized assessment tool that facilitates diagnosis, uniform patient monitoring, and comparison of treatment outcomes between different centers both in routine clinical practice and in research.MethodsTo develop this tool, published literature on assessment tools was searched on various databases. A panel of 12 steering committee members conducted an advisory board meeting to review the findings. Specific outcome measures to be included in a comprehensive assessment tool and follow‐up sheet were then collated following consensus approval from the panel. The tool was further validated for content and revised with expert recommendations to arrive at the finalized Nasal Polyp Patient Assessment Scoring Sheet (N‐PASS) tool.ResultsThe N‐PASS tool was developed by integrating the subjective and objective measures for CRS assessment. Based on expert opinions, N‐PASS was revised to be used as an easy‐to‐use guidance tool that captures patient‐reported and physician‐assessed components for comprehensively assessing disease status and response to treatment.ConclusionThe N‐PASS tool can be used to aid in the diagnosis and management of CRS cases with nasal polyps. The tool would also aid in improved monitoring of patients and pave the way for an international disease registry.Level of evidenceOxford Level 3.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of chronic rhinosinusitis with nasal polyps: Development of the Nasal Polyp Patient Assessment Scoring Sheet tool

Alsaleh,

Kamal,

Hopkins

et al. 2024

Laryngoscope Investig Oto

View full text Add to dashboard Cite

show abstract

“…Open access dermatitis 24 and eosinophilic esophagitis. 25 To date, three biologics have been assessed and approved by the European Union for managing severe CRSwNP, [26][27][28] after being studied for asthma: omalizumab, an IgE antibody 29 ; dupilumab, an anti-interleukin (IL)-4-α chain receptor 30 ; and mepolizumab, an IL-5 antagonist. 31 In France, only dupilumab and mepolizumab are reimbursed in case of severe uncontrolled CRSwNP despite the use of nasal and systemic corticosteroid and endoscopic sinus surgery.…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 99%

Study protocol: the biologics in severe chronic rhinosinusitis with nasal polyps survey

Favier,

Daveau,

Carsuzaa

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionChronic rhinosinusitis with nasal polyps (CRSwNP) is a frequent condition affecting approximately 2% of the population. Medical treatment consists long-term use of intranasal corticosteroids and short-term use of oral corticosteroids, in adjunct with saline solution rinses. Surgical management is proposed in patients who failed after medical treatment. In France, two biologics are reimbursed in case of severe uncontrolled CRSwNP despite medical treatment and endoscopic sinus surgery. Waiting for head-to-head biologics comparison, studies should report the efficacy and safety of biologics in large real-life cohorts. This study protocol describes the aims and methods of a prospective, observational, national, multicentric cohort of patients with CRSwNP treated with biologics.Methods and analysisThe BIOlogics in severe nasal POlyposis SurvEy is a French multicentre prospective observational cohort study. The main aim is to assess the efficacy and tolerance of biologics in patients with CRSwNP, with or without association with other type 2 diseases, and to determine the strategies in case of uncontrolled disease under biologics. Patients over 18 years old requiring biologics for CRSwNP in accordance with its marketing approval in France (ie, severe nasal polyposis, with lack of control under nasal corticosteroid, systemic corticosteroids and surgery) are invited to participate. Collected data include topical history of surgical procedures and biologics, medication and use of systemic corticosteroids, visual analogical scales for specific symptoms, Sino-Nasal Outcome Test-22 questionnaire, nasal polyp score, asthma control test, Lund-Mackay score on CT scan and IgE concentration and eosinophilic count on blood sample.Trial registrationNCT05228041/DRI_2021/0030.

show abstract

Therapie der chronischen Rhinosinusitis mit Polyposis nasi (CRScNP) mit monoklonalen Antikörpern (Biologika): S2k-Leitlinie der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie (DGHNO-KHC) und der Deutschen Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM)

Pfaar

Beule²,

Laudien³

et al. 2023

HNO

View full text Add to dashboard Cite

ZusammenfassungMonoklonale Antikörper (sog. Biologika) können bei chronischer Rhinosinusitis mit Nasenpolypen (CRScNP, im englischen Sprachgebrauch CRSwNP) im Rahmen ihrer Zulassung verordnet werden. Allerdings ist die Verordnung auf die schwere CRScNP ohne Krankheitskontrolle begrenzt, wobei bestimmte Voraussetzungen zu beachten sind. Derzeit sind Dupilumab, Omalizumab und Mepolizumab zugelassen, in der Literatur gibt es entsprechende Evidenz für ihre Wirksamkeit und Sicherheit. Es ist davon auszugehen, dass zukünftig weitere Biologika in dieser Indikation zugelassen werden. Die Schwere der Erkrankung sollte vor Therapieeinleitung sowie die Wirksamkeit dieser Therapie nach einem angemessenen Zeitraum objektiv und subjektiv überprüft werden. Hierfür kann der in diesem aktualisierten Leitlinien-Kapitel vorgeschlagene Dokumentationsbogen verwendet werden. Bei Vorliegen von relativen Kontraindikationen sollte nur nach differenzierter Abwägung durch erfahrene Ärzt*innen und als Einzelfallentscheidung ein Therapieversuch mit Biologika erfolgen. Zusammenfassend hat das vorliegende Leitlinien-Kapitel zum Ziel, angesichts der zunehmenden Evidenz zur Therapie mit diesen Substanzen bzw. der zunehmenden Zahl an Zulassungen unterschiedlicher Biologika zu einer qualitativ hochwertigen Versorgung von erwachsenen Patient*innen mit dieser Therapieform beizutragen.

show abstract

Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study

Cited by 21 publications

References 0 publications

Assessment of chronic rhinosinusitis with nasal polyps: Development of the Nasal Polyp Patient Assessment Scoring Sheet tool

Assessment of chronic rhinosinusitis with nasal polyps: Development of the Nasal Polyp Patient Assessment Scoring Sheet tool

Study protocol: the biologics in severe chronic rhinosinusitis with nasal polyps survey

Contact Info

Product

Resources

About